POXEL : Espoir avec la nouvelle équipe?

BCF64

31 août 2025 •20:40

France-headquartered Poxel S.A., a clinical-stage biopharmaceutical company on Friday announced the appointment of Nicolas Trouche as Chief Executive Officer. He replaces Thomas Kuhn who has resigned as Chief Executive Officer, with immediate effect as of July 31.

Nicolas Trouche has worked in several technology start-ups and has developed and restructured B2B industrial and commercial and service companies.

The company also announced significant changes within the Board of Directors. The changes follow the agreement signed by Poxel and its directors with the senior creditor of the company, in the context of the filing for the insolvency and request for opening of reorganization proceedings with the Court for Economic Activities of Lyon.

Accordingly, all the current directors of the company, Pascale Boissel, Richard Kender, Thomas Kuhn and Khoso Baluch, have submitted their resignations with immediate effect as of July 31. At its meeting on July 31, the Board of Directors of the company decided to replace them individually by co-optation with immediate effect by the following new directors viz. Sophie Jacq Lapointe; Nicolas Trouche; Amit Kohli and Alexandre Bragadir.

These co-optations would be subject to ratification at the next general meeting of shareholders of the Company.


Sophie Jacq Lapointe and Amit Kohli are considered to be independent directors.

Sophie Jacq Lapointe has been appointed by the new Board of Directors, as Chairman of the Board of Directors, succeeding Khoso Baluch. With over 20 years of experience in the pharmaceutical industry, Sophie has held numerous executive roles and has contributed to many commercial successes in oncology, immunology, neuroscience, rare diseases, and endocrinology.

Amit Kohli has over 3 decades of leadership experience operating at intersection of science, finance and commercialization.

Alexandre Bragadir has been a Senior Investment Director at IPF Partners, a fund specializing in non-dilutive financing for innovative healthcare companies across Europe.

For comments and feedback contact: